By exercising its option to collaborate on the development of aprocitentan, Janssen Biotech Inc. will provide Idorsia with a milestone payment of $230 million. When Johnson & Johnson acquired Actelion, its R&D unit was spun off as an independent company, Idorsia.
“I am delighted by Janssen’s decision to collaborate on the development of aprocitentan, which is a strong endorsement for our product,” Jean-Paul Clozel, CEO of Idorsia, said in a statement.
The two companies intend to jointly develop and commercialize aprocitentan, which is used to treat high blood pressure. The medication will be tested in an upcoming phase 3 study, led by Idorsia, on patients with what is called “resistant hypertension”. Janssen will oversee the submission for any additional indications.
A subsidiary of Johnson & Johnson, Janssen will receive sole worldwide commercialization rights. Idorsia is entitled to royalty payments on any future net sales generated.
“With this decision, Janssen has recognized the potential of aprocitentan, the latest product from a research effort that was initiated nearly 30 years ago and resulted in a broad understanding of the endothelin system,” said Martine Clozel, Chief Scientific Officer of Idorsia.
The treatment could have many other potential applications in addition to hypertension. “This makes the collaboration with Janssen even more meaningful for us,” added Clozel.